Background and Aims: The impact of coronavirus dis-ease-2019 (COVID-19) on liver function remains to be fully elucidated. This study was designed to investigate such and determine the clinical significance in determining mortality risk. Methods: A retrospective study was conducted in pa-tients with COVID-19 from March 2020 to July 2020. Clini-cal details were retrieved from electronic medical records to obtain clinical characteristics, medical history, laboratory tests, therapeutic intervention, and outcome data. Results: A total of 184 patients with COVID-19 were included (medi-an age: 45.5 years), comprised of 62.5％ men. In total, 22 (12.0％) patients had severe infection and 162 (88.0％) had mild to moderate infection. Overall, 95 (51.6％) showed ab-normal liver function test (LFT) and 17 (9.2％) showed nor-mal LFT at admission. The median age, hospital stay, and LFT were significantly higher in severe vs. non-severe infec-tion (p<0.001). Out of 12 deaths, the majority were due to severe infection (n=11). Deaths were also due to acute res-piratory distress syndrome (n=5), cardiac reasons (n=3), and sepsis with multiorgan failure (n=3). The median age, hospital stay and number of intensive care unit admissions were higher in patients having abnormal LFT compared to normal LFT. Incidence of elevated aspartate aminotrans-ferase (42.8％ and 40.4％), alanine transaminase (43.7％ and 41.6％), and hypoalbuminemia (71.4％ and72.7％) at admission and discharge were more common in severe infection. The mean survival was significantly lower in se-vere infection compared to those with non-severe disease (17.2 vs. 52.3 days; p<0.001). Conclusions: Incidence of abnormal liver function was higher in patients with severe COVID-19 and was associated with prolonged hospital stay; mortality was associated with severity of COVID-19. For rul-ing out the risk of liver injury, it is crucial to vigilantly moni-tor the liver function parameters in patients with COVID-19 admitted to hospital.